Astria Therapeutics (ATXS)

• Market cap: $701M
• 1 day: -1.51%
• 5 days: -0.64%
• 1 month: 61.64%
• 3 months: 78.08%
• 6 months: 184.44%
• Year to date: 38.57%
• 1 year: 4.72%
• 5 years: 56.94%
• 10 years: -97.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Employees: 78